VC firms
Hopen Life Science Ventures invests in exceptional early-to mid-stage life science opportunities.
Overview
Employees
1-10
Investment Type
Venture Capital
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 9, 2015 | NeoChord Secures $20 Million Series C Financing | Eden Prairie, Minn., June 9 2015 – NeoChord, a medical technology company, announced today it has closed an oversubscribed $20 million Series C financing round led by Deerfield Management, with participation from Baird Capital's Venture Cap... |
| Jul 22, 2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| Apr 22, 2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| Apr 21, 2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| Oct 17, 2012 | Tolera Therapeutics Closes $5.5M Series B-3 Financing | Tolera Therapeutics Inc., a Kalamazoo, Michigan-based biotechnology company focusing on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets, has closed its $5.5m Series B-3 financing. The r... |
| ProNAi raises $60 million to advance treatment to combat lymphoma | Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round. The latest fundraise will help support... |
Reviews 0
FAQ about Hopen Life Science Ventures
What has the press written about Hopen Life Science Ventures?
Parsers VC has collected 7 articles mentioning Hopen Life Science Ventures, among them “NeoChord Secures $20 Million Series C Financing” (Jun 9, 2015) and “MoneyTree Reports $121M in MI Venture Deals Last Quarter” (Jul 22, 2014).
Is Hopen Life Science Ventures still active?
Yes, Hopen Life Science Ventures is active; its latest activity on Parsers VC dates from Apr 10, 2023.